Press Release

Oncorus Presents Preclinical Data Supporting the Advancement of its Lead Oncolytic Virus Therapy Clinical Candidate, ONCR-177

Oncorus, Inc., an oncolytic virus therapeutics company focused on driving innovation to transform outcomes for cancer patients, unveiled preclinical data yesterday supporting the clinical advancement of its lead oncolytic virus candidate, ONCR-177, during an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019.

Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications

Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy  Clinical Candidate for Multiple Solid Tumor Indications

Dr. Ted Ashburn, CEO will give an update on the company’s pipeline and business at a presentation today at 7:30 AM EST at the Piper Jaffray 30th Annual Health Care Conference in New York City, highlighting key accomplishments from 2018 to date and outlining near- and long-term value drivers for the company.

Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types, today announced that preclinical data about its oncolytic Herpes simplex virus (oHSV) immunotherapy platform will be presented at the American Association of Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL. 

Oncorus®, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference

Oncorus®, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference

Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced that its Chief Executive Officer and co-founder, Mitchell H. Finer, PhD, will present a company overview at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 3:30pm Eastern Time. The event will be held in New York at the Lotte New York Palace.

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

Oncorus, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme (GBM), today announced the appointment of Christophe Quéva, Ph.D., as Chief Scientific Officer and Senior Vice President, Research. The company also announced the addition of Eric M. Sullivan as Senior Vice President, Finance & Operations and Treasurer, and Michael Paglia as Vice President, Chemistry, Manufacturing and Controls. 

Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC

Oncorus, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme (GBM), today announced that Astellas Venture Management LLC (“AVM”), the corporate venture arm of Astellas Pharma Inc., has provided Series A financing support to the company, increasing its Series A proceeds to $61 million.